A detailed history of Nisa Investment Advisors, LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 905 shares of RLAY stock, worth $5,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares
905
Previous 860 5.23%
Holding current value
$5,755
Previous $9,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

BUY
$7.5 - $12.07 $337 - $543
45 Added 5.23%
905 $7,000
Q4 2023

Jan 25, 2024

SELL
$6.01 - $11.48 $13,240 - $25,290
-2,203 Reduced 71.92%
860 $9,000
Q3 2023

Nov 02, 2023

BUY
$8.24 - $12.97 $131 - $207
16 Added 0.53%
3,063 $25,000
Q2 2023

Aug 11, 2023

BUY
$9.99 - $18.27 $6,813 - $12,460
682 Added 28.84%
3,047 $38,000
Q1 2023

May 02, 2023

BUY
$15.0 - $22.76 $375 - $569
25 Added 1.07%
2,365 $39,000
Q4 2022

Feb 02, 2023

SELL
$14.16 - $24.02 $254 - $432
-18 Reduced 0.76%
2,340 $35,000
Q3 2022

Nov 07, 2022

SELL
$18.07 - $31.37 $12,377 - $21,488
-685 Reduced 22.51%
2,358 $52,000
Q2 2022

Aug 03, 2022

BUY
$13.31 - $34.88 $5,816 - $15,242
437 Added 16.77%
3,043 $51,000
Q1 2022

Apr 29, 2022

BUY
$20.26 - $32.36 $405 - $647
20 Added 0.77%
2,606 $78,000
Q4 2021

Feb 03, 2022

BUY
$26.0 - $37.03 $37,882 - $53,952
1,457 Added 129.05%
2,586 $57,000
Q3 2021

Oct 18, 2021

SELL
$29.75 - $37.99 $88,952 - $113,590
-2,990 Reduced 72.59%
1,129 $36,000
Q2 2021

Aug 06, 2021

SELL
$27.5 - $38.19 $14,850 - $20,622
-540 Reduced 11.59%
4,119 $151,000
Q4 2020

Jan 25, 2021

BUY
$35.51 - $54.03 $165,441 - $251,725
4,659 New
4,659 $194,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $765M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.